Business Wire

SHIPPEO

13.10.2021 13:12:05 CEST | Business Wire | Press release

Share
Shippeo Tops 103% Annual Growth, Becomes World's Most Recommended Real-time Transportation Visibility Provider

Shippeo , a global leader and European specialist in real-time transportation visibility, announced today 103% year-on-year growth in subscription revenues and 181% net retention rate. The visibility solutions provider maintains the fastest growing customer base in Europe, having expanded its presence globally with the acquisition of several new high-profile customers currently being deployed in North America, Latin America, and APAC.

Since January, Shippeo has welcomed several new large international brands, including Coca-Cola HBC, one of the largest strategic bottling partners of The Coca-Cola Company; Nexans, a global player in energy transition; XPO Logistics, an American freight transportation company; and Woco Group, a global automotive component specialist, who supplies major OEMs.

A number of other category-leading brands have also chosen Shippeo’s real-time visibility solution, including Sappi, a leading producer of coated graphic paper, packaging and specialty papers; Conad, an Italian retail brand operating one of the largest supermarket chains in Italy; Fnac Darty Group, a French multinational electrical retailing company; Studio Moderna, an e-commerce company primarily operating across Central and Eastern Europe; and IDS, a Dutch 4PL logistics control tower specialist.

“Our very high net retention rate is a direct result of customers choosing to take fuller advantage of our expanding product portfolio, which now includes dock visibility and paperless visibility. Our ocean visibility has also become particularly popular as factors including Covid, the Suez blockage, and a global shortage of containers only intensifies the focus on the performance of this critical transport mode,” says Lucien Besse, COO of Shippeo .

“Shippeo has been recognized with a 98% recommendation rate on Gartner Peer Insights by our customers as at October 13, 2021*. I’m particularly proud of this achievement. Nothing is more important to us than delivering value to our customers and this is a fantastic result,” says Besse .

Shippeo’s team has expanded to over 230, with more than 90 new team members joining since January. Shippeo is on track to have more than doubled its staff year-on-year by the end of 2021. In addition, a number of senior profiles joined the company, including Nicolas Doucet, Strategic Alliance Director, previously at PTV Group; Guy-Pascal Bourlard, Head of Quality Assurance, previously at Amazon; Olivier Marcellin, Product Director, previously at Criteo; Marius Neuhäuser, Head of Solution Consulting, Alessandro De Martini, Business Development Director Italy, previously Country Manager at Transporeon and Bas Kramer, Business Development Director Benelux.

Furthermore, Shippeo is now expanding its operations into North America. As part of this strategic expansion, the company has welcomed Christopher Mazza as Senior Vice President, International Growth who will be responsible for leading the company’s activities in the region and growing Shippeo’s customer base. Christopher has extensive experience in the transportation and logistics industry, having participated in the creation of ClearMetal where he played an integral role in business development before joining project44 following the company's acquisition.

Recently the company announced new strategic partnerships with Savoye, a leading designer and integrator of complete supply chain solutions, and Tesisquare, a leading provider of supply chain execution applications. Shippeo has also partnered with Siemens DL, a leading IT provider in global supply chain management solutions.

The collaborations aim to make it easier for customers to overcome transport management challenges by leveraging deep TMS integrations, making it simple to take advantage of real-time visibility’s many benefits.

“We’re incredibly proud of the momentum we’re experiencing and the fact that we’ve maintained 0% customer churn throughout the year,” says Besse . “It’s really thanks to our extremely dedicated teams, our holistic customer-centric approach and a focus on the quality of our solution implementations, relationships and accelerated time to value for customers.”

Learn more

*https://www.gartner.com/reviews/market/real-time-transportation-visibility platforms/vendor/shippeo/product/shippeo-visibility-platform

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of
Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye